fda depression - Search News

FDA approves Johnson & Johnson’s nasal spray for depression

Newsweek on MSN · 5h

FDA Approves Nasal Spray for Depression

The nasal spray Spravato, which is made from the drug esketamine, had been approved in 2019 for patients who failed to respond to at least two oral antidepressants.

FDA approves first nasal spray treatment for severe depression

The FDA approved Johnson & Johnson’s Spravato nasal spray as a stand-alone treatment for patients suffering from severe depression. It is now the first-ever stand-alone therapy for treatment-resistant depression.

CNN on MSN · 15h

FDA approves standalone use of J&J’s ketamine-derived depression treatment

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression, the company said on Tuesday.

Pharmaceutical Technology4h

J&J’s Spravato receives FDA label expansion for depression monotherapy

The FDA’s decision marks J&J's Spravato as the first monotherapy for adults with treatment-resistant depression.

J&J’s Spravato Makes Headway in Tough Depression Space With Monotherapy Approval

Esketamine, the active ingredient in Spravato, is a non-selective, non-competitive antagonist of the NMDA receptor, a known ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results